Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cancer Immunotherapy
100%
Receptor Signaling
100%
Intracellular Delivery
100%
Pattern Recognition Receptors
100%
Cell-penetrating Peptide
100%
Clinical Trials
66%
In Cancer
66%
Cancer Vaccine
66%
Innate Immune Response
33%
Cell-based
33%
Tumor Immunity
33%
Recent Advances
33%
Antigen-presenting Cells
33%
T Cells
33%
Peptide Vaccine
33%
Response Rate
33%
Dendritic Cells
33%
Melanoma
33%
MHC Class II
33%
Tumor Antigen
33%
Antigen Presentation
33%
Human Cancer
33%
Clinical Response
33%
T-cell Mediated
33%
Autoreactive T Cells
33%
Anticancer Drugs
33%
MHC Class I
33%
Clinical Efficacy
33%
US FDA
33%
Antitumor Immune Response
33%
Adaptive Immunity
33%
Protein Vaccine
33%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
33%
CTLA-4 Inhibitors
33%
Antigenic Peptide
33%
Innate Immune Signaling
33%
Sipuleucel-T
33%
Medicine and Dentistry
Cancer Immunotherapy
100%
T Cell
100%
Pattern Recognition Receptor
100%
Cell Penetrating Peptide
100%
Clinical Trial
50%
Immunotherapy
50%
Tumor Vaccine
50%
Innate Immunity
25%
Melanoma
25%
Neoplasm
25%
Immune Response
25%
Peptide Vaccine
25%
Antigen Presenting Cell
25%
Dendritic Cell
25%
Tumor Antigen
25%
Antigen Presentation
25%
Adaptive Immunity
25%
Cytotoxic T Lymphocyte Antigen 4 Antibody
25%
Anticancer Drug
25%
Castration Resistant Prostate Cancer
25%
Cancer Peptide
25%
Sipuleucel T
25%
Immunology and Microbiology
T Cell
100%
Peptides
100%
Cancer Immunotherapy
100%
Pattern Recognition Receptor
100%
Immunotherapy
50%
Tumor Vaccine
50%
Innate Immune System
25%
Immune Response
25%
Peptide Vaccine
25%
Dendritic Cell
25%
Tumor Antigen
25%
Antigen-Presenting Cell
25%
Prostate
25%
Antigen Presentation
25%
MHC Class I
25%
MHC Class II
25%
Adaptive Immune System
25%
Cancer Peptide
25%
Sipuleucel-T
25%
Cytotoxic T Lymphocyte Antigen 4 Antibody
25%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Immunotherapy
100%
Cell Penetrating Peptide
100%
Pattern Recognition Receptor
100%
Clinical Trial
40%
Tumor Vaccine
40%
Neoplasm
20%
Peptide Vaccine
20%
Melanoma
20%
Anticancer Drug
20%
Tumor Antigen
20%
Cytotoxic T Lymphocyte Antigen 4 Antibody
20%
Sipuleucel T
20%
Castration Resistant Prostate Cancer
20%
Protein Vaccine
20%